The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma.
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Biond; Evaxion Biotech; OncoC4; Turnstone Bio
Honoraria - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Regeneron; Roche; Sellas Life Sciences; Takeda; Turnstone Bio; Ultimovacs; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Roche; Sellas Life Sciences; Turnstone Bio; Turnstone Bio; Ultimovacs; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Moderna Therapeutics; Novartis; Roche
 
Amrutesh Puranik
No Relationships to Disclose
 
Teruyuki Mitzutani
No Relationships to Disclose
 
Tomoaki Muramatsu
No Relationships to Disclose
 
Judith D. Goldberg
No Relationships to Disclose
 
Janice M. Mehnert
Stock and Other Ownership Interests - Pfizer
Honoraria - HMP; Medscape
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Sanofi/Regeneron; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); bristol myers squibb (Inst); GV20 Therapeutics; Incyte (Inst); Kinnate Biopharma (Inst); macrogenics (Inst); macrogenics (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Xiaochun Li
No Relationships to Disclose
 
Benjamin A. Levinson
No Relationships to Disclose
 
Omid Hamid
Stock and Other Ownership Interests - Bactonix
Honoraria - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Consulting or Advisory Role - Alkermes; Amgen; Bactonix; BeiGene; BioAtla; Bristol-Myers Squibb; Eisai; Genentech; Georgiamune; GigaGen; GlaxoSmithKline; Grit Biotechnology; Idera; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Janssen; KSQ Therapeutics; Merck; Moderna Therapeutics; NGM Biopharmaceuticals; Novartis; Obsidian Therapeutics; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Vial; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Inderjit Mehmi
Stock and Other Ownership Interests - Delcath Systems; Immunocore; Inate Pharma
Speakers' Bureau - Bristol-Myers Squibb; Immunocore
 
Mark B Faries
Consulting or Advisory Role - Bristol-Myers Squibb; Instil Bio; Merck; Novartis; Regeneron
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Leadership - Bicara Therapeutics
Stock and Other Ownership Interests - Apricity Health; Bicara Therapeutics; Pionyr; Torque
Consulting or Advisory Role - AstraZeneca; Bioentre; Bristol-Myers Squibb; Catalym; Checkpoint THerapeutics; Compass Therapeutics; Corner Therapeutics; Curis; Genentech/Roche; Gossamer Bio; Immunocore; Iovance Biotherapeutics; Kairos Therapeutics; Merck Sharp & Dohme; Novartis; Rheos Medicines; Surface Oncology; Zumutor Biologics
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Elizabeth Iannotti Buchbinder
Employment - Alexion Pharmaceuticals (I); Takeda (I)
Consulting or Advisory Role - Instil Bio; Iovance Biotherapeutics; Merck; Nektar; Novartis; Pfizer; Sanofi; Werewolf Pharma; Xilio Therapeutics
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Genentech/Roche; Lilly; Novartis
 
Patrick Alexander Ott
Consulting or Advisory Role - Bristol-Myers Squibb; Evaxion Biotech; Immunetune; LG Chem; Merck; Novartis
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Neon Therapeutics (Inst); Oncorus; Pfizer (Inst); Xencor
Expert Testimony - Boehringer Ingelheim
 
Sofia Bajwa
No Relationships to Disclose
 
Perla Arriola
No Relationships to Disclose
 
Naika Legros
No Relationships to Disclose
 
Ryan J. Sullivan
Consulting or Advisory Role - Bristol-Myers Squibb; maren; Merck; Novartis; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)